Back to search

Article

Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer

2020-09-14

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Although activating mutations of the KRAS GTPase are the predominant dependency present in >90% of PDAC patients, targeting KRAS mutants directly has been challenging in PDAC. Similarly, strategies targeting known KRAS downstream effectors have had limited clinical success due to feedback mechanisms, alternate pathways a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
71164de4-74e1-57b4-a6ed-c77c728db8cb
DOI
10.1101/2020.09.14.295394
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancerDOI 10.1101/2020.09.14.295394
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.Semantic proximity
Oncogenic KRAS signalling in pancreatic cancerSemantic proximity
Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibitionSemantic proximity
PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.Semantic proximity
Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.Semantic proximity
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.Semantic proximity
Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity
Kras as a key oncogene and therapeutic target in pancreatic cancerSemantic proximity
Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.Semantic proximity
Oncogenic dependency plays a dominant role in the immune response to cancer.Semantic proximity
Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACSemantic proximity
Select a neighboring publication to make it the new centre.